evipedia.ai
← Back

Pentadecanoic Acid for Health & Longevity

Evidence Review created on 09/26/2026 using AI4L / Opus 5.5

Also known as: C15:0, C15, Pentadecylic Acid, n-Pentadecanoic Acid, FA 15:0, FA15, fatty15

Motivation

Pentadecanoic acid (C15:0) is a saturated fat with fifteen carbon atoms, found in small amounts in butter, cheese, whole milk and the meat of grazing animals. It has drawn interest because people with more of it in their blood tend to have healthier metabolism, and it is now sold as a purified daily supplement.

For decades, scientists measured it mainly as a sign of how much dairy fat someone ate. Its reputation changed when researchers caring for aging Navy dolphins proposed that it acts directly on cells, calming inflammation and supporting the cell’s energy machinery, and suggested it may be a nutrient the body needs from food. That proposal, and the company built around it, have made it one of the more debated new longevity supplements.

This review examines what the human evidence shows about pentadecanoic acid for health and longevity, with a focus on blood sugar control, liver health and heart health. It covers how strong that evidence is, who produced it, which risks and unknowns exist, and how supplement protocols and blood testing are used in practice.

Benefits - Risks - Protocol - Conclusion

This section lists primary research, an independent academic review and critical expert commentary that together give a high-level overview of pentadecanoic acid from supportive and skeptical perspectives.

Note on priority experts: No relevant content on pentadecanoic acid was found from Andrew Huberman, Chris Kresser or Life Extension Magazine in web and on-site searches. Peter Attia’s only match is a July 2024 “Research Worth Sharing” newsletter whose subtitle names the geroprotective potential of pentadecanoic acid, but whose text contains no discussion of it; it is not listed for lack of substantive content. Rhonda Patrick’s only relevant content is a short segment inside a members-only Q&A episode; it is not listed because its content is paywalled. Lifespan.io’s only matching item is a republished Seraphina Therapeutics press release; it is not listed because it is promotional and comes from the same company as the first item above.

Grokipedia

Pentadecylic acid

An AI-generated encyclopedia entry covering chemistry, dietary sources, the essentiality debate and both supplementation trials; useful as a broad primer, though its health summary leans on manufacturer-affiliated research.

Examine

No Examine article on pentadecanoic acid exists; direct searches of examine.com for “pentadecanoic acid” and “C15:0” returned no results as of 26 September 2026.

ConsumerLab

What is C15:0 fatty acid (found in fatty15), and does it have health benefits?

A medically reviewed answer, updated September 2024, stating that no clinical studies support the marketed hair, skin, sleep and aging-related uses; its detailed analysis of trials, dosing and cost is members-only.

Systematic Reviews

This section lists systematic reviews and meta-analyses relating blood pentadecanoic acid levels to diabetes, cardiovascular disease and cancer, plus one on the cholesterol effect of butter, the main risk of the dairy-fat route.

No systematic review or meta-analysis of pentadecanoic acid supplementation, its adverse effects or its safety exists; the risk side is represented only by the butter review, and the other reviews pool observational data on blood levels, not supplement trials.

Mechanism of Action

Most proposed mechanisms come from cell and animal studies by researchers affiliated with Seraphina Therapeutics, the maker of fatty15 (Venn-Watson & Schork, 2023).

  • Energy sensing and growth signaling: activates AMPK (AMP-activated protein kinase, the cell’s fuel gauge) and inhibits mTOR (mechanistic target of rapamycin, a growth-signaling hub), pathways also targeted by metformin and rapamycin.
  • Fat-burning gene switches: partially activates PPAR-α and PPAR-δ (peroxisome proliferator-activated receptors, which switch on fat-burning genes).
  • Membrane stability: as a saturated fat it resists oxidation and is proposed to protect cell membranes against ferroptosis (iron-driven cell death from damaged membrane fats) (Venn-Watson, 2024).
  • Endocannabinoid signaling: its metabolite pentadecanoylcarnitine activates CB1 and CB2 (receptors of the body’s own cannabis-like signaling system) in cell assays (Venn-Watson et al., 2022).

Competing explanation: blood levels may mainly mark dairy intake and fiber-driven production from propionate, a short-chain fat made by gut bacteria (Weitkunat et al., 2017), so the human associations may not be causal.

Pharmacology: No human elimination half-life has been published. It circulates in phospholipids, triglycerides and red-cell membranes and is stored in fat tissue. Beta-oxidation (the mitochondrial process that burns fatty acids) yields acetyl-CoA (the standard two-carbon fuel unit bound to coenzyme A) plus propionyl-CoA (a three-carbon fragment), which vitamin B12- and biotin-dependent enzymes convert into an energy-cycle intermediate. No CYP (cytochrome P450, the main drug-metabolizing enzymes) pathway is known to be relevant. Selectivity is low: it acts on many targets at similar concentrations.

Historical Context & Evolution

Pentadecanoic acid was never developed as a treatment. For decades laboratories used it as an analytical reference standard and, because microbes in cattle and sheep stomachs make odd-chain fats, as a blood marker of dairy-fat intake. A synthetic iodine-labeled derivative, iodofiltic acid, was developed separately as a heart-imaging agent.

Interest in direct health effects grew when large cohorts found opposite associations for different saturated fats. In the EPIC-InterAct study, higher blood odd-chain saturated fats tracked lower type 2 diabetes risk while even-chain saturated fats tracked higher risk (Forouhi et al., 2014). Around the same time, US Navy veterinarians linked odd-chain fats in fish diets to improved metabolic health in aging dolphins (Venn-Watson et al., 2015). In 2020 the lead researcher proposed pentadecanoic acid as an essential fatty acid (Venn-Watson et al., 2020), and Seraphina Therapeutics commercialized a purified form.

Opinion has since moved in two directions. Supporters point to cell studies showing anti-inflammatory activity and to two small human trials, one partly manufacturer-funded, in which blood levels rose and some liver and cholesterol markers improved (Robinson et al., 2024; Chooi et al., 2024). Critics note that no nutrition authority lists it as essential, that most mechanistic data come from the manufacturer, that part of blood pentadecanoic acid is made from dietary fiber, and that a 2026 genetic cause-and-effect analysis did not support a causal cardiovascular benefit (Steffen et al., 2026). Neither position yet rests on long-term outcome trials, and new trial data could move the assessment in either direction.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: supplementation has been tested only in two small 12-week randomized trials, and neither replicated a clinical endpoint or an outcome-validated marker such as LDL in more than one trial.

Medium 🟩 🟩

Lower Type 2 Diabetes Risk

People with higher blood pentadecanoic acid develop type 2 diabetes less often, a finding replicated across cohorts in Europe, the United States, Asia and Australia (Imamura et al., 2018; Chen et al., 2026). Proposed mechanisms include AMPK activation and better insulin action in muscle. The data are observational, and blood levels partly reflect dairy and fiber intake, so confounding (other diet or lifestyle factors behind the link) is possible. No supplement trial has measured diabetes incidence.

Magnitude: Hazard ratio (the relative rate of new cases over time) 0.80 per 10th-to-90th percentile difference (the gap between a person at the 10th and one at the 90th percentile) of blood levels in 63,682 adults, about 20% fewer new cases; relative risk (the ratio of risk between higher and lower groups) 0.82 (18% lower) in the 2026 update.

Low 🟩

Liver Enzymes and Liver Fat ⚠️ Conflicted

In a partly manufacturer-funded trial, 200 mg daily lowered GGT (gamma-glutamyl transferase, a liver-stress enzyme) versus placebo (Robinson et al., 2024). Adding 300 mg to a weight-loss diet did not reduce liver fat further (Chooi et al., 2024). Net: modest enzyme gains, no added liver-fat benefit.

Magnitude: GGT fell 11 U/L more than placebo; ALT (alanine aminotransferase, a liver-injury enzyme) fell a median 29 U/L only in participants reaching plasma levels above 5 µg/mL; liver fat fell 33% with diet plus supplement versus 30% with diet alone.

LDL Cholesterol ⚠️ Conflicted

Adding 300 mg daily to a weight-loss diet in women with fatty liver lowered LDL beyond diet alone (Chooi et al., 2024). A 200 mg trial found no LDL difference (Robinson et al., 2024). Net: the purified supplement appears LDL-neutral to mildly favorable.

Magnitude: Direction only: LDL fell further with supplementation during diet-induced weight loss, and the trial abstract reports no between-group figure; the 200 mg trial reported no significant LDL change.

Cardiovascular Disease and Blood Pressure ⚠️ Conflicted

One meta-analysis links higher blood levels with modestly lower cardiovascular disease risk (Trieu et al., 2021); an earlier, smaller one (13 versus 18 studies) found no significant link (Liang et al., 2018). Genetic testing found no causal blood-pressure effect (Steffen et al., 2026). Net: association plausible, causation unproven.

Magnitude: Relative risk 0.88 (12% lower) for the highest versus lowest third of blood levels across 18 studies; 1.47 mm Hg lower systolic blood pressure per standard deviation (a typical spread) of blood level, not supported by Mendelian randomization (a genetic cause-and-effect test).

Hemoglobin and Red Blood Cell Health

In the 200 mg trial, participants who reached plasma levels above 5 µg/mL gained hemoglobin while others did not (Robinson et al., 2024). This was an after-the-fact, non-randomized subgroup comparison linked to higher adherence. Dolphin feeding studies showed similar effects (Venn-Watson et al., 2020).

Magnitude: Median hemoglobin change of +0.6 g/dL in the above-threshold group versus −0.5 g/dL on placebo over 12 weeks.

Lower Cancer Risk

In a meta-analysis, pentadecanoic acid was the only one of 18 blood fatty acids significantly linked to lower colorectal cancer risk (Lu et al., 2023). Cell studies show selective anticancer activity (Venn-Watson, 2025). Human evidence is observational and limited.

Magnitude: Pooled odds ratio (a case-control estimate of relative risk) 0.60 for colorectal cancer with high versus low blood levels, about 40% lower odds, from a small pool of blood-based studies.

Speculative 🟨

Longevity-Pathway and Anti-Inflammatory Activity

In human cell systems, pentadecanoic acid lowered inflammatory signals and shared 24 activities with rapamycin (Venn-Watson & Schork, 2023). No human aging outcome has been measured; the basis is cell-based and manufacturer-affiliated.

Cognitive and Mood Support

In cell assays it inhibited FAAH (fatty acid amide hydrolase, which breaks down cannabis-like signals) and MAO-B (monoamine oxidase B, which breaks down dopamine) (Venn-Watson & Jensen, 2025). The basis is mechanistic only.

Gut Microbiome Shift

Supplementation increased Bifidobacterium adolescentis in one trial (Chooi et al., 2024), and gut bacteria make pentadecanoic acid from inulin fiber in mice (Wei et al., 2023). Health relevance is unmeasured.

Sleep Quality

Marketed for deeper sleep because, in cells, a metabolite activates cannabinoid and serotonin receptors and blocks histamine receptors (Venn-Watson et al., 2022). No human sleep outcome exists; the basis is mechanistic only.

Skin and Hair Health

Marketed for healthier hair and skin. A metabolite lowered inflammatory signals in cell systems relevant to skin disease (Venn-Watson et al., 2022); no hair or human skin data exist, so the basis is mechanistic only.

Benefit-Modifying Factors

  • Genetic variation: No gene variant has been tested. In the 200 mg trial (Robinson et al., 2024), blood-level changes ranged from −1.21 to +5.31 µg/mL; adherence explained only part, pointing to inherited or microbial differences in absorption or metabolism.
  • Baseline blood level: Proposed deficiency is ≤0.2% of circulating fatty acids (Venn-Watson, 2024). Trial improvements appeared only in those reaching above 5 µg/mL (Robinson et al., 2024), so low starters and strong responders may gain most; both thresholds come from manufacturer-affiliated research.
  • Sex: In pooled cohorts, the diabetes association was stronger in women than in men (Imamura et al., 2018). The liver trial enrolled only women, and the young-adult trial did not analyze sexes separately.
  • Pre-existing conditions: Trial signals come from people with overweight, metabolic syndrome (clustered high blood pressure, blood sugar and waist size) or fatty liver; effects in metabolically healthy adults are unstudied. Elevated liver enzymes at baseline may leave more room for measurable improvement.
  • Age: Trials enrolled adults aged 18–25 and women with fatty liver. In adults over 65, blood levels showed no link to overall mortality (de Oliveira Otto et al., 2018); a trial in adults 55 and older is planned.
  • Dietary pattern: Habitual whole-fat dairy and fermentable-fiber intake raise baseline blood levels, likely shrinking the added effect of a supplement in heavy dairy or fiber eaters.

Potential Risks & Side Effects

High 🟥 🟥 🟥

LDL Cholesterol Rise From Dairy-Fat Sources

Raising pentadecanoic acid by eating more butter or full-fat dairy also delivers palmitic and myristic acids, which raise LDL. Randomized trials show butter raises LDL compared with olive oil (Khaw et al., 2018; Engel & Tholstrup, 2015). This evidence tested butter, not the purified supplement, which has not raised LDL in trials. The risk matters most for people with high LDL or familial hypercholesterolemia (an inherited cause of very high LDL).

Magnitude: LDL rose 0.38 mmol/L (about 15 mg/dL) more with 50 g of butter daily than with olive oil over 4 weeks.

Medium 🟥 🟥

No risk reaches Medium: safety data for the purified supplement come from two 12-week randomized trials with roughly 50 supplemented participants (Robinson et al., 2024; Chooi et al., 2024), which reported no significant adverse events and are too small to detect uncommon harms.

Low 🟥

Speculative 🟨

Interactions With Mood-Active Drugs

In cells, a metabolite activates cannabinoid and serotonin (5-HT1A and 5-HT1B) receptors (Venn-Watson et al., 2022), and the fatty acid inhibits MAO-B (Venn-Watson & Jensen, 2025). Additive drug effects are theoretical; no human reports exist.

Blunted Muscle-Building Signaling

Cell-level AMPK activation and mTOR inhibition resemble metformin, which blunted muscle growth from strength training in older adults (Walton et al., 2019). Human effects are untested; the basis is mechanistic only.

Risk-Modifying Factors

  • Genetic variation: Carriers of APOE4 (a variant of a cholesterol-transport gene) and people with familial hypercholesterolemia show larger LDL rises from saturated fat, making the dairy-fat route riskier than the purified supplement.
  • Inborn errors of propionate metabolism: In propionic acidemia and methylmalonic acidemia (inherited disorders in clearing propionyl-CoA), breakdown of odd-chain fats adds to an already toxic metabolite load.
  • Baseline biomarkers: High baseline LDL or ApoB (apolipoprotein B, a count of cholesterol-carrying particles) raises the stakes of the dairy route. Already-high blood pentadecanoic acid means exposure beyond tested levels.
  • Sex and pregnancy: No sex differences in adverse effects are known. Safety of supplemental doses in pregnancy and breastfeeding is unstudied; trials excluded pregnant participants.
  • Pre-existing conditions: Fat-malabsorption conditions such as pancreatic insufficiency (too few digestive enzymes from the pancreas) may reduce uptake. Vitamin B12 deficiency could, in principle, slow clearance of the propionyl-CoA byproduct.
  • Age: Older adults more often take MAO-B inhibitors (Parkinson’s drugs that slow dopamine breakdown) or serotonergic drugs (antidepressants and migraine drugs acting on serotonin), the theoretical interaction concern. No trial has yet reported results in adults over 55.

Key Interactions & Contraindications

  • MAO-B inhibitors (Parkinson’s drugs that slow dopamine breakdown: selegiline, rasagiline, safinamide): Monitor, theoretical. Cell-level MAO-B inhibition could add to drug effects, in principle raising dopamine-related side effects. No human reports exist; prescriber review before starting is the mitigating step.
  • Serotonergic drugs (SSRIs, selective serotonin reuptake inhibitors such as sertraline and escitalopram; triptans, migraine drugs such as sumatriptan): Monitor, theoretical. A metabolite activates serotonin receptors in cells, possibly adding serotonin-excess symptoms (agitation, tremor, sweating); none reported. Watching for these after starting mitigates.
  • Cannabinoid drugs (dronabinol, nabilone): Caution, theoretical. Cannabinoid-receptor activation and FAAH inhibition in cells could add sedation or mood effects. Starting at 100 mg and observing for drowsiness mitigates.
  • mTOR inhibitors and metformin (immune-suppressing drugs, also studied for longevity, that block the growth signal: sirolimus, everolimus; plus metformin): Monitor, theoretical. Additive AMPK and mTOR effects could deepen immune suppression or blunt training-induced muscle gains. No clinical reports; routine labs suffice.
  • Fat-absorption blockers (over-the-counter orlistat; bile acid sequestrants, cholesterol drugs that bind bile in the gut: cholestyramine, colesevelam): Monitor. They may reduce absorption, lowering blood levels. Separating doses by at least 4 hours mitigates.
  • Over-the-counter antihistamines (diphenhydramine, cetirizine, famotidine): Minor, theoretical. A metabolite blocks histamine H1 and H2 receptors in cells, possibly adding drowsiness. No mitigation beyond observation is known.
  • Supplements with additive effects: Monitor. Inulin, other fermentable fibers and cannabidiol overlap mechanistically; fiber raises blood levels, cannabidiol adds cannabinoid effects, and berberine adds AMPK activation. Blood-level testing avoids overshooting untested ranges.
  • Dietary dairy fat: Caution when combined with supplements. Adds to blood levels and raises LDL through other saturated fats. A lipid panel 8–12 weeks after increasing dairy detects the rise.
  • Other interventions: Monitor. Rapamycin-based longevity protocols share mTOR effects, possibly adding to their immune-suppressing and muscle-blunting effects; calorie-restricted weight-loss diets produced most liver benefits in the diet trial, making attribution to the supplement difficult.

Populations who should avoid Pentadecanoic Acid:

  • People with propionic acidemia or methylmalonic acidemia, unless supervised by a metabolic specialist
  • Pregnant or breastfeeding individuals (no safety data for supplemental doses)
  • Children and adolescents under 18 years (supplement doses unstudied)
  • For the dairy-fat route: people with LDL at or above 190 mg/dL or diagnosed familial hypercholesterolemia
  • People with known hypersensitivity to any capsule ingredient

Risk Mitigation Strategies

  • Capsule rather than butter when LDL is high: Using a purified 100–200 mg capsule instead of adding butter avoids the saturated-fat LDL rise; an LDL or ApoB check 8–12 weeks after any dairy increase detects it.
  • Baseline and 12-week labs: A lipid panel, liver enzymes and complete blood count before starting and at 12 weeks detect unexpected LDL, liver-enzyme or hemoglobin changes, given the thin safety record.
  • Drug-interaction review: Prescriber review before starting, for anyone taking MAO-B inhibitors, serotonergic antidepressants, cannabinoid drugs or mTOR inhibitors, addresses the theoretical additive-effect risk.
  • Staying within tested doses: Keeping intake at or below 300 mg daily, the highest studied dose, limits exposure to untested amounts and unknown long-term effects.
  • Screening for inborn errors: Avoiding supplementation in known propionate-metabolism disorders, unless a metabolic specialist supervises, prevents added propionyl-CoA load.
  • Pausing in pregnancy and breastfeeding: Stopping supplementation during pregnancy and breastfeeding avoids unstudied fetal and infant exposure.
  • Monitoring for training blunting: Tracking strength and muscle measures every 8–12 weeks in people doing resistance training detects any blunted muscle-building response, the theoretical mTOR-related risk.

Therapeutic Protocol

  • Manufacturer protocol (Seraphina Therapeutics): One 100 mg capsule of purified pentadecanoic acid (fatty15) administered orally once daily, the dose promoted by co-founder Stephanie Venn-Watson; this dose has not been tested in a published trial.
  • Trial-based protocol (University of California San Diego): 200 mg daily for 12 weeks, tested by Jeffrey Schwimmer’s group in overweight young adults (Robinson et al., 2024); 300 mg daily accompanied a Mediterranean-style diet in Singapore (Chooi et al., 2024).
  • Food-first approach: Increasing whole-fat dairy and beef or lamb fat, in which pentadecanoic acid makes up roughly 1% of the fat; favored by those preferring whole foods, but it brings the saturated-fat LDL trade-off.
  • Fiber-based approach: 30 g daily of inulin raised blood levels about 17% in a crossover trial by the German Institute of Human Nutrition group (Weitkunat et al., 2017), an indirect route via gut propionate.
  • Time of day: The young-adult trial gave the dose each morning (Robinson et al., 2024) and the planned older-adult trial with the first meal (NCT07812792); food is assumed to aid absorption, though this is untested.
  • Half-life: No human elimination half-life has been published; blood levels rose over 12 weeks of daily dosing, and red-cell membrane levels likely reflect about 3–4 months, the red-cell lifespan.
  • Single versus split dosing: All trials used one daily dose; no data support splitting the dose.
  • Genetic factors: No gene variant is known to change the dose; APOE4 carriers and people with familial hypercholesterolemia face less LDL risk with the capsule than with the dairy route.
  • Sex: No sex-specific dosing exists; one trial enrolled only women and the other both sexes, without sex-specific analyses.
  • Age: Only adults have been studied; a planned trial tests 200 and 300 mg in adults 55 and older, so current dosing for older adults extrapolates from younger groups.
  • Baseline biomarkers: Testing blood pentadecanoic acid before starting identifies low baseline levels; a plasma target above 5 µg/mL has been proposed in manufacturer-affiliated research and guides dose adjustment in some practices.
  • Pre-existing conditions: Evidence comes from overweight, metabolic syndrome and fatty liver populations; fat malabsorption may call for level-guided dose adjustment.

Discontinuation & Cycling

  • Intended duration: Proponents frame it as an ongoing nutrient taken indefinitely; human data cover only 12 weeks, so long-term continuous use is untested.
  • Withdrawal effects: None reported. Stopping is expected to let blood levels drift back toward dietary baseline over weeks to months.
  • Tapering: Not required; no rebound or dependence mechanism is known.
  • Cycling: No evidence supports cycling for efficacy, and no loss of effect over time has been described.
  • Situational pauses: Pausing during pregnancy or when starting an interacting drug removes unstudied exposures; blood levels can be rechecked before restarting.

Sourcing and Quality

  • Purified free fatty acid: fatty15 (Seraphina Therapeutics) contains FA15, a purified pentadecanoic acid ingredient in 100 mg capsules; the young-adult trial used this ingredient (Robinson et al., 2024).
  • Algal triglyceride forms: Microalgae-derived oils rich in odd-chain fats, such as Pentadecyl® from Aurantiochytrium limacinum, exist but have only animal data (Yoneda-Yasui et al., 2026).
  • Third-party testing: A certificate of analysis showing at least 98% purity, identity by gas chromatography, and heavy-metal and solvent limits; seals from NSF International or U.S. Pharmacopeia (independent supplement-testing organizations) where available.
  • Oxidative stability: As a saturated fat it resists rancidity far better than fish oil, so refrigeration is typically unnecessary; capsule fillers and excipients still vary by brand.
  • Food sources: Butter, cheese, whole milk, cream, and beef or lamb fat; amounts vary with animal feed and the fat content of the product.
  • Lower-cost alternatives: Generic pentadecanoic acid products exist, and ConsumerLab has covered lower-cost options (members-only), but independent purity data on generics are limited.

Practical Considerations

  • Time to effect: Blood-level and liver-enzyme changes appeared by 12 weeks in trials; red-cell membrane incorporation may take 3–4 months; any effect on disease risk would take years and remains unmeasured.
  • Common pitfalls: Treating essential-nutrient status as settled; assuming the 100 mg label dose matches trial doses; missing doses, since lower adherence tracked non-response; adding butter for pentadecanoic acid without checking LDL.
  • Regulatory status: Sold in the United States as a dietary supplement, not an approved drug. The National Academies, a nonprofit scientific body with no revenue tied to supplement sales, do not list it as essential (Dow, 2025).
  • Cost and access: About US$50 per month for the branded product, plus about US$199 for the manufacturer’s blood test (Dow, 2025). Insurers do not reimburse it, and no payer incentive favoring supplement or diet is evident.
  • Level testing: Blood tests are offered by the manufacturer and specialty laboratories; reference ranges and units are not standardized across assays.

Interaction with Foundational Habits

  • Sleep: Direction: none established. “Deeper sleep” marketing rests on cell data showing cannabinoid, serotonin and histamine receptor activity of a metabolite; no human sleep outcome has been measured. Morning dosing with food matches trial practice and avoids untested evening use.
  • Nutrition: Direction: potentiating. Whole-fat dairy and fermentable fiber (inulin, legumes, oats) raise blood levels. In the Singapore trial, a Mediterranean-style weight-loss diet produced most liver benefits, with the supplement adding LDL lowering (Chooi et al., 2024). Taking it with a fat-containing meal is standard practice.
  • Exercise: Direction: unknown, possibly blunting. AMPK activation and mTOR inhibition resemble metformin, which blunted muscle growth from strength training in older adults (Walton et al., 2019); no study has tested pentadecanoic acid alongside training. Separating dosing from post-workout meals is a theoretical precaution only.
  • Stress management: Direction: none established. FAAH inhibition in cells could raise anandamide (a calming endocannabinoid), and a metabolite activates serotonin receptors; no human cortisol, anxiety or mood outcomes have been measured with supplementation.

Monitoring Protocol & Defining Success

Baseline testing: Before starting, a baseline panel documents starting pentadecanoic acid status and the markers where trial signals appeared: a blood fatty-acid test (plasma or red-cell), liver enzymes, a lipid panel with ApoB, and a complete blood count with hemoglobin and RDW (red cell distribution width, the variation in red-cell size). Adding hs-CRP (high-sensitivity C-reactive protein, a general inflammation marker), HbA1c (glycated hemoglobin, a three-month blood-sugar average) and ferritin covers inflammation, blood sugar and iron claims. Fasting samples keep lipid and glucose results comparable.

Ongoing monitoring: Repeat testing at 12 weeks, matching trial duration, shows whether blood levels rose and whether liver enzymes, LDL or hemoglobin moved. Thereafter, testing every 6–12 months continues while supplementation lasts, plus a lipid check 8–12 weeks after any change in dose or dairy intake.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pentadecanoic acid Plasma above 5 µg/mL; 0.4–0.64% of membrane fatty acids (proposed) Confirms uptake Targets come from manufacturer-affiliated research; no conventional reference range; plasma and red-cell assays differ; fasting not required
ALT Under 25 U/L Liver-cell stress Alanine aminotransferase; conventional upper limit about 30–40 U/L; pair with AST (aspartate aminotransferase, a liver and muscle enzyme) and GGT
AST Under 25 U/L Liver and muscle stress Conventional under 40 U/L; avoid hard exercise 48 hours before
GGT Under 20 U/L Liver stress Gamma-glutamyl transferase; conventional under about 36–50 U/L; raised by alcohol
LDL cholesterol Under 100 mg/dL Dairy-fat LDL effect Low-density lipoprotein; conventional under 130 mg/dL; fasting preferred; pair with ApoB
ApoB Under 80 mg/dL Atherogenic particle count Apolipoprotein B; conventional under about 100–130 mg/dL; many longevity clinicians target lower
Hemoglobin Men 14–16 g/dL; women 13–15 g/dL Red-cell signal Conventional men 13.5–17.5 g/dL, women 12–15.5 g/dL; pair with RDW and ferritin
RDW 11.5–13.0% Red-cell health Red cell distribution width; primary endpoint of the planned older-adult trial; conventional up to about 14.5%
hs-CRP Under 1.0 mg/L Inflammation High-sensitivity C-reactive protein; conventional under 3.0 mg/L; repeat after acute illness
HbA1c Under 5.4% Blood-sugar control Glycated hemoglobin; conventional normal under 5.7%; no fasting needed
Ferritin 40–150 ng/mL Iron stores Conventional about 15–300 ng/mL; inflammation raises it; best paired with hs-CRP, morning fasting draw

Qualitative markers tracked alongside laboratory results:

  • Energy and daytime fatigue
  • Sleep quality and duration
  • Digestive tolerance, such as stool changes or nausea
  • Mood and stress resilience
  • Skin and hair condition (marketed but untested claims)
  • Strength and training progress in people doing resistance exercise

Emerging Research

  • Older-adult red blood cell trial: A Phase 2 randomized trial (NCT07812792) will give 200 mg, 300 mg or placebo daily for 12 weeks to 93 adults aged 55 and older, with RDW as primary endpoint and biological-age scores secondary; industry-sponsored and not yet recruiting.
  • Completed trials awaiting replication: The 30-person young-adult trial (NCT04947176) and the 88-person Singapore diet trial (NCT05259475) produced secondary liver, cholesterol and hemoglobin signals; larger confirmatory trials could strengthen or weaken them.
  • Causality testing: Mendelian randomization found no causal blood-pressure benefit (Steffen et al., 2026), weakening the cardiovascular case; similar genetic analyses for diabetes and liver outcomes could shift the picture in either direction.
  • Endogenous production: Gut bacteria convert fiber into pentadecanoic acid in mice (Wei et al., 2023) and in humans via propionate (Weitkunat et al., 2017), raising the question whether fiber, not dairy or supplements, explains observational benefits.
  • Anticancer research: Cell studies report selective activity against B-cell lymphomas (cancers of antibody-producing white blood cells) with alterations in CCND3 (a gene driving cell division) (Venn-Watson, 2025) and breast cancer stem-like cells (To et al., 2020); no human cancer trial exists.
  • Essentiality debate: Independent reviewers call essential status plausible but unproven (Ciesielski et al., 2024); controlled depletion and repletion studies would settle whether a true deficiency state exists.

Conclusion

Pentadecanoic acid is a trace saturated fat from dairy and grazing-animal meat, now sold as a purified daily capsule promoted for healthy aging. The most consistent human finding is that people with more of it in their blood develop type 2 diabetes less often, with weaker, mixed links to heart disease and colon cancer. These patterns come from observation, and blood levels also reflect dairy and fiber intake, so they do not show that the capsule delivers that benefit. Direct tests of the supplement are few, small and short: blood levels rise, with hints of better liver enzymes, cholesterol and hemoglobin, but no added liver-fat benefit beyond diet and no long-term outcome data. A genetic test of cause and effect did not support a heart benefit.

Most laboratory and animal evidence, and the essential-nutrient idea itself, come from the founder of the company that sells the leading product, and one human trial was partly funded by that company. The sharpest critique comes from a consumer group that takes no company money, and the national nutrition body that does not call it essential has no stake in sales. Insurers play no evident financial role.

Short-term use has shown no notable side effects; long-term safety is unknown. Getting more through butter and cheese carries a cholesterol cost. For health-focused adults, the evidence describes a low-risk supplement with an uncertain payoff, whose clearest signal involves blood sugar, with only tentative hints for liver enzymes.

Top - Benefits - Risks - Protocol